Presseaussendungen zu "Renal"

328 Aussendungen
vorige Seite Seite 1 von 22 nächste Seite

Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy …

OTE0011
19.03.2019 23:47
OTE0003
19.11.2018 13:09

Primary Care Diabetes Europe Issues Call to Action Against Clinical Inertia in the Treatment of Type-2 Diabetes

Research identifies lack of primary care physician adherence to treatment guidelines among the challenges to optimal care for patients with type-2 diabetes

OTE0003
06.11.2018 09:02
OTE0001
09.10.2018 08:01

Vifor Pharma Wins 2018 Pharma 4.0 Award for Implementation of Augmented Reality System

Vifor Pharma Group today announced that the company and partner Goodly Innovations were awarded the 2018 Pharma 4.0 Award for the innovation of the year in manufacturing execution systems in the pharma …

OTE0002
28.09.2018 09:01

Corvia Medical gibt starkes, positives Einjahresergebnis aus der randomisierten, scheinkontrollierten klinischen Studie REDUCE LAP-HF I bekannt

Corvia Medical, Inc., ein privates Unternehmen, das ein erstklassiges Gerät für strukturelle Herzerkrankungen und Herzinsuffizienz herstellt, hat heute die Einjahres-Folgedaten aus der klinischen Studie …

OTS0145
27.08.2018 18:01

New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018)

Serves Key Patient Populations Including, Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic, Inflammatory Diseases

OTE0003
07.06.2018 09:17

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks

Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients With Highly Active Multiple Sclerosis

- Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo

OTE0003
02.05.2018 10:32
vorige Seite nächste Seite